ISRCTN98865222 https://doi.org/10.1186/ISRCTN98865222

Trial of topical British Anti-Lewisite (BAL) to prevent cyclophosphamide induced alopeciae

Submission date	Recruitment status	[ ] Prospectively registered
01/07/2001	No longer recruiting	[ ] Protocol
Registration date	**Overall study status**	[ ] Statistical analysis plan
01/07/2001	Completed	[ ] Results
Last Edited	**Condition category**	[ ] Individual participant data
26/02/2015	Cancer	[ ] Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
- -

Contact details
UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

Additional identifiers

Protocol serial number
BAL

Study information

Scientific Title
Trial of topical British Anti-Lewisite (BAL) to prevent cyclophosphamide induced alopeciae

Study objectives
Not provided at time of registration

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Primary study design
Interventional

Study design
Randomised controlled trial

Study type(s)
Treatment

Health condition(s) or problem(s) studied
Lung (non-small cell) cancer

Interventions
1. BAL Group: Chemotherapy, single-agent cyclophosphamide plus topical application of BAL. BAL lotion to be applied to posterior half of the scalp including occipital parietal areas two hours before and within 15 minutes of completing cyclophosphamide infusion. BAL to be left on the scalp for two to three hours.
2. Control Group: Chemotherapy, single-agent cyclophosphamide.

Intervention Type
Drug

Phase
Not Applicable

Drug/device/biological/vaccine name(s)
British Anti-Lewisite, cyclophosphamide

Primary outcome(s)
Not provided at time of registration

Key secondary outcome(s)
Not provided at time of registration

Completion date
31/12/2003

Eligibility

Key inclusion criteria
1. Lung cancer patients due to receive single-agent cyclophosphamide
2. Hair to be cut as short as possible before application of BAL

Participant type(s)

Patient

Healthy volunteers allowed
No

Age group
Adult

Sex
All

Key exclusion criteria
Not provided at time of registration

Date of first enrolment
01/01/2000

Date of final enrolment
31/12/2003

Locations

Countries of recruitment
United Kingdom

England

Study participating centre
MRC Clinical Trials Unit
London
United Kingdom
NW1 2DA

Sponsor information

Organisation
Cancer Research UK (CRUK) (UK)

ROR
https://ror.org/054225q67

Funder(s)

Funder type
Charity

Funder Name
Cancer Research UK

Alternative Name(s)
CR_UK, Cancer Research UK - London, Cancer Research UK (CRUK), CRUK

Funding Body Type
Private sector organisation

Funding Body Subtype
Other non-profit organizations

Location
United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary